Superior TAVR Valve Sapien 3 and Sapien 3 Ultra available for all patients diagnosed with severe, symptomatic aortic stenosis.-Edwards Life Sciences
Edwards Lifesciences Corporation announced FDA approval to expand use of the Edwards SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valve systems to the treatment of severe, symptomatic aortic stenosis (AS) patients who are determined to be at low risk of open-heart surgery.
"The PARTNER 3 Trial demonstrated that low-risk patients treated with the SAPIEN 3 TAVR experienced extraordinary outcomes with 1.0 percent rates of death or disabling stroke at one year, a short length of stay and 96 percent discharged to home or self-care. SAPIEN 3 is the only valve to achieve superiority over surgery based on the prespecified primary endpoint," said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Medical Center and professor of medicine at the Columbia University College of Physicians and Surgeons.
"Today's FDA approval of SAPIEN 3 TAVR will expand access to this proven therapy, which should be considered the preferred treatment for the majority of low-risk severe AS patients." Leon is the national co-principal investigator of the PARTNER 3 Trial.
The SAPIEN 3 TAVR's low-risk approval was based on data from the landmark PARTNER 3 Trial, an independently evaluated, randomized clinical trial comparing outcomes between TAVR and open-heart surgery. TAVR with the SAPIEN 3 system achieved superiority, with a 46 percent reduction in the event rate for the primary endpoint of the trial, which was a composite of all-cause mortality, all stroke and rehospitalization at one year. The data were presented in March at the American College of Cardiology's 68th Annual Scientific Session and simultaneously published in the New England Journal of Medicine.See-"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients"- Michael J. Mack, M.D., Martin B. Leon, M.D., Vinod H. Thourani, M.D., Raj Makkar, M.D., et al., for the PARTNER 3 Investigators*
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.